JP2023502517A5 - - Google Patents
Info
- Publication number
- JP2023502517A5 JP2023502517A5 JP2022530172A JP2022530172A JP2023502517A5 JP 2023502517 A5 JP2023502517 A5 JP 2023502517A5 JP 2022530172 A JP2022530172 A JP 2022530172A JP 2022530172 A JP2022530172 A JP 2022530172A JP 2023502517 A5 JP2023502517 A5 JP 2023502517A5
- Authority
- JP
- Japan
- Prior art keywords
- application
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025253228A JP2026048848A (ja) | 2019-11-25 | 2025-12-16 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940209P | 2019-11-25 | 2019-11-25 | |
| US62/940,209 | 2019-11-25 | ||
| US201962944890P | 2019-12-06 | 2019-12-06 | |
| US62/944,890 | 2019-12-06 | ||
| PCT/US2020/061923 WO2021108353A1 (en) | 2019-11-25 | 2020-11-24 | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025253228A Division JP2026048848A (ja) | 2019-11-25 | 2025-12-16 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023502517A JP2023502517A (ja) | 2023-01-24 |
| JP2023502517A5 true JP2023502517A5 (https=) | 2023-12-01 |
Family
ID=76130717
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022530172A Pending JP2023502517A (ja) | 2019-11-25 | 2020-11-24 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法 |
| JP2025253228A Pending JP2026048848A (ja) | 2019-11-25 | 2025-12-16 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025253228A Pending JP2026048848A (ja) | 2019-11-25 | 2025-12-16 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230025600A1 (https=) |
| EP (1) | EP4065173A4 (https=) |
| JP (2) | JP2023502517A (https=) |
| KR (1) | KR20220106779A (https=) |
| CN (1) | CN115397473A (https=) |
| AU (1) | AU2020391623A1 (https=) |
| BR (1) | BR112022009672A2 (https=) |
| CA (1) | CA3162282A1 (https=) |
| IL (1) | IL293209A (https=) |
| MX (1) | MX2022006289A (https=) |
| PH (1) | PH12022551098A1 (https=) |
| TW (1) | TW202133885A (https=) |
| WO (1) | WO2021108353A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019392090A1 (en) | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| EP4096717B1 (en) | 2020-01-31 | 2024-12-11 | Innate Pharma | Treatment of cancer |
| KR20230091885A (ko) * | 2020-09-17 | 2023-06-23 | 어젠시스 인코포레이티드 | 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)로 암을 치료하는 방법 |
| MX2023005873A (es) * | 2020-11-25 | 2023-06-05 | Innate Pharma | Tratamiento del cancer. |
| WO2024012536A1 (zh) * | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体、其抗体药物偶联物及应用 |
| WO2024129552A2 (en) * | 2022-12-16 | 2024-06-20 | Merck Sharp & Dohme Llc | Combination therapy of a pd-1 antagonist, a lag3 antagonist and an antibody drug conjugate that binds 191p4d12 protein for treating patients with cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008202217B2 (en) * | 2002-08-16 | 2012-07-26 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 191PAD12(b) useful in treatment and detection of cancer |
| MX347954B (es) * | 2010-09-29 | 2017-05-19 | Agensys Inc | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. |
| ES2781523T3 (es) * | 2012-07-12 | 2020-09-02 | Hangzhou Dac Biotech Co Ltd | Conjugados de moléculas de unión celular con agentes citotóxicos |
| US20150231241A1 (en) * | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US10669338B2 (en) * | 2016-06-17 | 2020-06-02 | Immunomedics, Inc. | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 |
-
2020
- 2020-11-24 KR KR1020227020967A patent/KR20220106779A/ko active Pending
- 2020-11-24 JP JP2022530172A patent/JP2023502517A/ja active Pending
- 2020-11-24 BR BR112022009672A patent/BR112022009672A2/pt unknown
- 2020-11-24 CN CN202080094301.9A patent/CN115397473A/zh active Pending
- 2020-11-24 CA CA3162282A patent/CA3162282A1/en active Pending
- 2020-11-24 TW TW109141151A patent/TW202133885A/zh unknown
- 2020-11-24 US US17/779,068 patent/US20230025600A1/en active Pending
- 2020-11-24 MX MX2022006289A patent/MX2022006289A/es unknown
- 2020-11-24 IL IL293209A patent/IL293209A/en unknown
- 2020-11-24 EP EP20893544.5A patent/EP4065173A4/en active Pending
- 2020-11-24 WO PCT/US2020/061923 patent/WO2021108353A1/en not_active Ceased
- 2020-11-24 PH PH1/2022/551098A patent/PH12022551098A1/en unknown
- 2020-11-24 AU AU2020391623A patent/AU2020391623A1/en active Pending
-
2025
- 2025-12-16 JP JP2025253228A patent/JP2026048848A/ja active Pending